You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Todos also announced a $23.8 million sales agreement this week with an unnamed Wisconsin laboratory covering testing equipment and supplies.
Alphazyme will manufacture three Codexis enzymes, including a new high-fidelity DNA polymerase, and gain comarketing rights to certain other Codexis enzymes.
Novacyt has initially committed to supply 288,000 tests per week to the DHSC, and it has an option to expand the agreement.
Under the agreement, Bioneer will supply instruments, nucleic acid extraction reagents, and COVID-19 test kits, which will be placed at medical institutions in Qatar.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
Cellectricon is researching the spread of neurodegenerative disease-associated peptides that characterize Alzheimer's disease and Parkinson's disease.
RNAssist's products are designed for biomolecule stabilization, tissue fixation, and microbial inactivation in a range of applications including RNA sequencing.
Ginkgo will acquire Beacon optofluidic platforms from Berkeley Lights and incorporate them into its automated genetic engineering foundries.
Integrated DNA Technologies said it will act as the primary supplier of next-generation sequencing oligo products for Clear Lab's NGS-based Clear Safety platform.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.